Letrozole

编者按：2025年美国临床肿瘤学会（ASCO）年会于当地时间5月30日-6月3日在美国芝加哥盛大召开。作为肿瘤学领域全球瞩目的学术盛会，本届ASCO年会汇聚了众多国际顶尖专家，分享突破性研究成果与临床实践洞见。在乳腺癌领域，广受关注的SERENA-6研究发布了题为“Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2-advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.”的最新报告，为HR+/HER2-晚期乳腺癌的一线治疗策略优化提供了关键科学依据。SERENA-6研究是全球性双盲III期试验，旨在评估在HR+/HER2-晚期乳腺癌一线治疗中，利用ctDNA动态监测技术实现早期干预，并改用Camizestrant与CDK4/6抑制剂联合治疗的疗效和安全性。SERENA-6研究已取得阳性结果，肿瘤瞭望特邀复旦大学附属肿瘤医院李俊杰教授、浙江大学医学院附属第二医院陈益定教授、哈尔滨医科大学附属第二医院郭宝良教授，于ASCO会议现场第一时间进行数据解读！聚焦当前HR+/HER2-晚期乳腺癌一线治疗实况内分泌治疗地位举足轻重，一线标准方案尚存优化空间《肿瘤瞭望》：内分泌治疗在HR+/HER2-乳腺癌的治疗中扮演着重要角色，其与CDK4/6抑制剂的联用是当前HR+/HER2-乳腺癌晚期一线的标准方案。请您谈谈当前HR+/HER2-晚期乳腺癌一线治疗现状及目前临床中有哪些未被满足的需求呢？李俊杰 教授复旦大学附属肿瘤医院毋庸置疑，当前CDK4/6抑制剂联合内分泌治疗已成为HR+/HER2-晚期乳腺癌患者一线治疗的标准方案。即便对于内脏转移或内脏危象的HR+/HER2-乳腺癌患者，CDK4/6抑制剂联合内分泌治疗仍然是指南推荐的一线治疗方案。但在晚期一线相关研究中，我们看到，有10%-20%的患者在第一次随访时，生存曲线会呈现出下降趋势。因此，基于当前HR+/HER2-晚期乳腺癌患者的治疗现状，我们应进一步讨论到底哪些患者是原发CDK4/6抑制剂耐药人群？我们能否在这些患者接受CDK4/6抑制剂治疗之前就将其筛选出来？此外，接受维持治疗的晚期患者，也会产生一定的不良反应，如何使这些患者在接受CDK4/6抑制剂治疗中有更多获益，也是我们要考量的。同时，不同的患者的复发时机也会不同，我们能否更早监测出容易复发的患者，早期给予特定性的干预，这也是当前研究的热点。陈益定 教授浙江大学医学院附属第二医院在所有乳腺癌患者中，HR+/HER2-乳腺癌患者数量是最多的，约70%的乳腺癌患者为HR+/HER2-亚型。正如李俊杰教授谈到的，CDK4/6抑制剂联合AI治疗是这部分患者的一线标准治疗方案，但这部分患者接受一线标准治疗后，还是会出现耐药甚至出现疾病进展。因此，如何克服耐药是我们目前亟需解决的问题。此外，对于即将接受CDK4/6抑制剂联合AI治疗的患者，我们能否在患者接受治疗前通过生物标志物（biomarker）等手段预测患者的治疗疗效，做到未卜先知，并提前进行相关干预，也是我们当前的研究方向。郭宝良 教授哈尔滨医科大学附属第二医院我认同前面两位教授所说的观点。实际上，CDK4/6抑制剂联合内分泌治疗作为一线治疗方案，其证据非常充分，PALOMA、MONARCH以及MONALEESA系列研究的数据都为其提供了有力支持，相关指南也广泛推荐这一方案。然而，目前临床中仍存在一些问题：第一，对于初始耐药的患者，我们可能尚未完全筛查出具体人群。第二，我们能否通过良好的生物标志物（biomarker）来指导治疗，从而找到确切有效的治疗方案？尤其是针对一些特殊人群，比如存在ESR1基因突变的患者，我们该如何应对？以上这些这都需要我们进行更深入的个体化考量，以制定更合适的治疗方案。突破HR+/HER2-晚期乳腺癌一线治疗困局SERENA-6研究结果重磅揭晓，阳性结果惊艳全球《肿瘤瞭望》：III期研究SERENA-6探索了ctDNA指导治疗切换的可行性，本次ASCO首次公布了该研究的具体数据。请您为我们分享并解读SERENA-6研究设计及主要结果？郭宝良 教授哈尔滨医科大学附属第二医院SERENA-6是一项III期双盲、随机研究，旨在评估Camizestrant与CDK4/6抑制剂（包括哌柏西利、瑞波西利、阿贝西利）联合治疗相较于AI与CDK4/6抑制剂联合治疗在疾病进展之前出现ESR1突变（ESR1m）的HR+/HER2-晚期乳腺癌中的疗效和安全性。研究共纳入3256例已接受至少6个月一线AI（阿那曲唑/来曲唑）+CDK4/6抑制剂治疗的HR+/HER2-晚期乳腺癌患者，每2-3个月进行一次ctDNA检测以筛查ESR1m，并与常规影像学检查同步进行。在315例检测到ESR1m且无疾病进展的患者中，按1:1比例随机分配至Camizestrant（75mg）联合持续CDK4/6抑制剂（类型和剂量保持不变）+AI安慰剂治疗组（Camizestrant治疗组；157例患者），或AI+CDK4/6抑制剂+Camizestrant安慰剂组（AI治疗组；158例患者），两组患者基线特征平衡。主要终点为研究者评估的PFS（根据RECIST v1.1标准）。中期分析计划在至少135个PFS事件后进行，并且所有患者都确保接受了至少一次治疗中肿瘤评估，若PFS有显著获益，则进行次要终点第二次PFS（PFS 2）和OS评估。截至2024年12月28日，共发生171起PFS事件，Camizestrant vs AI治疗组患者的中位PFS时间分别为：16.0个月vs 9.2个月，HR 0.44（95%CI：0.31-0.60）；P＜0.00001，12个月PFS率分别为60.7% vs 33.4%，24个月时为29.7%（95%CI：19.0-41.2）vs 5.4%（95%CI：0.7-18.2）。亚组分析结果显示，PFS获益在各亚组中均保持一致。Camizestrant和AI治疗组中分别发生的38例和47例PFS 2事件，PFS 2的风险比为0.52（95%CI：0.33-0.81；27%成熟度）。OS数据尚不成熟（12%）。Camizestrant +CDK4/6抑制剂治疗组显示出了较好的耐受性和安全性。因不良反应导致治疗中断的比率，Camizestrant治疗组为1.3%，AI治疗组为1.9%。通过本次大会上公布的数据，我们清晰地观察到，Camizestrant治疗组展现出了显著的治疗优势。这一数据结果着实令人惊喜，尤其是在如此大规模的III期临床研究中，首次公布相关数据便取得如此卓越的成绩，值得向相关团队表示祝贺！陈益定 教授浙江大学医学院附属第二医院SERENA-6研究公布的结果的确令人惊艳。我们看到在临床研究设计方面，该研究采用外周ctDNA作为考量指标。值得一提的是，在检测时，研究对象并非临床进展期的患者，而是ESR1突变患者，并被随机分为两组接受治疗。这一点至关重要，意味着在未来的治疗模式中，我们或许能够借助此类生物标志物（biomarker）以及液体活检技术，来指导后续治疗。这对于精准治疗而言，意义重大。而且该研究结果确实令人瞩目，为我们在晚期乳腺癌治疗领域的探索提供了更多有力证据。李俊杰 教授复旦大学附属肿瘤医院我个人非常喜欢SERENA-6这项临床研究。但比较遗憾的是，这是虽然是在全球开展的III期临床研究，但中国并没有研究中心参与其中。我欣赏它的原因在于，其设计既聪明又大胆，基于该研究良好的设计和令人惊艳的结果，该研究在ASCO年会上作为LBA研究公布的同时，又同期发表于NEJM杂志。首先，ctDNA的预后价值大家都很清楚，但目前相关临床试验开展较少，主要是因为ctDNA阳性的检出率不高。如果根据阳性检出结果进行随机分组，那么符合条件的人群会很少。由此可见，SERENA-6研究的实施难度非常大。该研究共筛选了约3300名患者，筛选后发现约16%的患者（即500多名患者）ctDNA检出为ESR1阳性，在这500多名患者中，还需进一步筛选出ESR1突变且尚未出现疾病临床或影像学进展的患者，最终得到315名患者，并按1∶1的比例进行随机分组。由此可见，研究人群的选择极为困难。然而，在精准找到这些患者后，我们立即改变一线内分泌解救治疗方案，采用升阶梯策略，并取得了阳性结果。其次，该研究再次证实，无论何时只要ctDNA检测呈阳性的患者，几乎都会在8-12个月内出现疾病进展。因此，在AI治疗组继续采用原方案治疗的情况下，得到了9.2个月的PFS。对此，我们有两个非常期待的答案：第一，我们能否找到更好的方法来检测ctDNA，以提高其阳性率和准确率，从而更精准地检测ESR1突变率？第二，我们也期待新型口服SERD药物Camizestrant能否在更广泛的人群中（甚至不需要检测ctDNA的情况下），在更前线的治疗中取得阳性结果。我们也期待未来中国参与的III期SERENA-4研究能为我们揭晓答案。△SERENA-4研究设计示意Tips：SERENA-4是一项多中心、随机双盲Ⅲ期研究，纳入既往未接受任何系统治疗的新诊断ER+/HER2-晚期乳腺癌患者，旨在评估Camizestrant联合哌柏西利对比阿那曲唑联合哌柏西利一线治疗的有效性和安全性，解答有关“在晚期初始治疗中，应用Camizestrant能否可进一步提升治疗获益”等关键问题。在晚期初始治疗中，应用Camizestrant能否进一步提升HR+/HER2-乳腺癌患者的治疗获益？欲知详情，请关注明晚《ASCO现场速递丨ASCO LBA&NEJM同步发表，新一代口服SERD助力HR+/HER2-mBC一线治疗优化（下篇）》发布。李俊杰 教授复旦大学附属肿瘤医院乳腺外科副主任医师、副教授，医学博士，硕导现担任乳腺外科行政副主任，浦东病区主任，科室教学秘书。2008年毕业于复旦大学临床医学七年制专业，至美国麻省总院癌症中心进行乳腺癌临床专科进修学习，专注于乳腺癌的临床和基础研究，参与并设计多项国际、国内多中心临床试验，在Annal of Oncology, Cancer Cell, JCO, Cancer Communications, JNCCN, IJS等权威杂志发表SCI论文20余篇。主持国自然面上项目一项，复旦大学青年临床科学家培养计划。中国抗癌协会乳腺癌专业委员会青年专家、中华医学会乳腺肿瘤学组青年专家、上海市抗癌协会乳腺癌专业委员会常委及秘书长、中国抗癌协会国际医疗交流委员会常委、中国抗癌协会乳腺肿瘤整合康复委员会常委、北京癌症防治学会乳腺青委副主任委员、中华乳腺病杂志中青年编委等职务。陈益定 教授浙江大学医学院附属第二医院，主任医师，乳腺外科主任，博士生导师中国抗癌协会乳腺癌专委会常务委员中国抗癌协会家族遗传性肿瘤专委会常务委员CSCO乳腺癌专家委员会委员中国医促会乳腺疾病分会常务委员浙江省医师协会乳腺肿瘤专委会副主委浙江省抗癌协会乳腺癌专委会候任主委郭宝良 教授哈尔滨医科大学附属第二医院乳腺二科主任主任医师、教授、博士生导师中国临床肿瘤协会乳腺癌专委会委员中国抗癌协会乳腺癌专业委员会委员中国医药教育学会乳腺疾病专业委员会常委中国医师协会乳腺疾病培训专家委员会委员中国医师协会外科学分会MDT专业委员会委员黑龙江省医学会乳腺疾病专委会主任委员（来源：《肿瘤瞭望》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer First and only next-generation oral SERD and complete ER antagonist to demonstrate consistent progression-free survival benefit in combination with widely approved CDK4/6 inhibitors in 1st-line advanced breast cancer WILMINGTON, DE, USA I June 01, 2025 I Positive results from the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation. These results will be presented today during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (abstract #LBA4) and simultaneously published in The New England Journal of Medicine . Results showed the camizestrant combination reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI] 0.31–0.60; p<0.00001) as assessed by investigator. Median PFS was 16.0 months for patients who switched to the camizestrant combination versus 9.2 months for the comparator arm. Importantly, a consistent PFS benefit was observed across all CDK4/6 inhibitors and clinically relevant subgroups in the trial, including analysis by age, race, region, time of ESR1 mutation detection and type of ESR1 mutation. The camizestrant combination was also associated with a meaningful delay in time to deterioration in quality of life, where in an exploratory endpoint, the camizestrant combination reduced the risk of deterioration in global health status and quality of life by 47% compared with the AI combination (HR 0.53; 95% CI, 0.33-0.82; nominal p<0.001). The median time to deterioration of global health status was 23.0 months in patients treated with the camizestrant combination, versus 6.4 months in patients that continued treatment with the AI combination (EORTC QLQ-C30). The camizestrant combination also delayed the time to deterioration of pain compared with the AI combination. Data for the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis. However, a trend toward extended treatment benefit was observed with the camizestrant combination based on PFS2 (HR 0.52; 95% CI 0.33-0.81; p=0.0038 [interim analysis threshold p=0.0001]). The trial will continue to assess OS, PFS2 and other key secondary endpoints. Nicholas Turner, MD, PhD, Professor of Molecular Oncology at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, UK,and co-principal investigator for the trial, said: “Today’s news marks a pivotal moment in breast cancer care and redefines how we think about drug resistance in this type of breast cancer. The results of the innovative SERENA-6 trial show that switching from an aromatase inhibitor to camizestrant in combination with any of the three CDK4/6 inhibitors after emergence of an ESR1 mutation more than halved the risk of disease progression or death and delayed deterioration in quality of life by nearly 18 months. This proactive approach exemplifies a new treatment strategy in oncology; by treating developing resistance before it causes disease progression and deterioration in quality of life, we can extend the benefit of 1st-line treatment to optimize patient outcomes.” Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “As the first pivotal trial to demonstrate the clinical value of monitoring circulating tumor DNA to detect emerging resistance and change therapy at the earliest opportunity; SERENA-6 is redefining the clinical paradigm in breast cancer. Camizestrant is the first and only next-generation oral SERD and complete estrogen receptor antagonist to demonstrate benefit in combination with widely approved CDK4/6 inhibitors in this 1st-line setting, and these results support its potential as a new standard-of-care endocrine therapy backbone in the treatment of HR-positive breast cancer.” Summary of results: SERENA-6 The safety profile of camizestrant in combination with palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent with the known safety profile of each medicine. Consistent with the longer duration of exposure to the combination of camizestrant and CDK4/6 inhibitors in the trial, Grade 3 or higher adverse events from all causes occurred in 60% of patients in the camizestrant arm versus 46% in the AI arm; the majority of which were hematological events typically associated with CDK4/6 inhibitor treatment and included neutropenia (45% vs. 34%), anemia (5% vs. 5%) and leukopenia (10% vs. 3%). If experienced, photopsia – reported as brief flashes of light in the peripheral vision – did not impact daily activities of patients in the trial and was reversible. There were no structural changes in the eye or changes in visual acuity. No new safety signals were identified and discontinuation rates were very low and similar in both arms, with 1% patients discontinuing camizestrant and 2% patients discontinuing an AI. Discontinuation of the CDK4/6 inhibitor occurred in 1% of patients in both arms of the trial. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a circulating tumor DNA (ctDNA)-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression. The novel trial design used ctDNA monitoring at the time of routine tumor scans to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations. Following detection of an ESR1 mutation without disease progression, the endocrine therapy of patients was switched to camizestrant from ongoing treatment with an AI, while continuing combination with the same CDK4/6 inhibitor. Based on the results of the SERENA-6 Phase III trial, camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) has been granted Breakthrough Therapy Designation (BTD) in the US by the Food and Drug Administration for the treatment of adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer upon emergence of ESR1 mutation during first-line endocrine-based therapy. Notes HR-positive breast cancer Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. 1 More than two million patients were diagnosed with breast cancer in 2022, with more than 665,000 deaths globally. 1 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis. 2 HR-positive breast cancer, characterized by the expression of estrogen or progesterone receptors, or both, is the most common subtype of breast cancer with 70% of tumors considered HR-positive and HER2-negative. 2 ERs often drive the growth of HR-positive breast cancer cells. 3 Globally, approximately 200,000 patients with HR-positive breast cancer are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target estrogen receptor (ER)-driven disease, which are often paired with CDK4/6 inhibitors. 4-6 However, resistance to CDK4/6 inhibitors and current endocrine therapies develops in many patients with advanced disease. 6 Once this occurs, treatment options are limited and survival rates are low with 35% of patients anticipated to live beyond five years after diagnosis. 2,6,7 Mutations in the ESR1 gene are a key driver of endocrine resistance and are widely tested for in clinical practice at time of disease progression on 1st-line therapies. 8,9 Thesemutations emerge during treatment of the disease, becoming more prevalent as the disease progresses and are associated with poor outcomes. 8,9 Approximately 30% of patients with endocrine sensitive HR-positive disease develop ESR1 mutations during 1st-line treatment without disease progression. 4 The optimization of endocrine therapy and overcoming resistance to enable patients to continue benefiting from these treatments, as well as identifying new therapies for those who are less likely to benefit, are active areas of focus for breast cancer research. SERENA-6 SERENA-6 is a Phase III, double-blind, randomized trial evaluating the efficacy and safety of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with HR-positive, HER2-negative advanced breast cancer (patients with either locally advanced disease, or metastatic disease) whose tumors have an emergent ESR1 mutation. The global trial enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer, undergoing treatment with an AI in combination with a CDK4/6 inhibitor as 1st-line treatment. The primary endpoint of the SERENA-6 trial is PFS as assessed by investigator, with secondary endpoints including OS, and PFS2 by investigator assessment. Camizestrant Camizestrant is an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist that is currently in Phase III trials for the treatment of HR-positive breast cancer. AstraZeneca’s broad, robust and innovative clinical development program, including the SERENA-6, SERENA-4, CAMBRIA-1 and CAMBRIA-2 trials, is evaluating the safety and efficacy of camizestrant when used as a monotherapy or in combination with CDK4/6 inhibitors to address a number of areas of unmet need in HR-positive, HER2-negative breast cancer. Camizestrant has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. In the SERENA-2 Phase II trial, camizestrant demonstrated PFS benefit versus fulvestrant irrespective of ESR1 mutation status or prior treatment with CDK4/6 inhibitors in patients with ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy. The SERENA-1 Phase I trial demonstrated that camizestrant is well tolerated and has a promising anti-tumor profile when administered alone or in combination with palbociclib, ribociclib and abemaciclib; three widely used CDK4/6 inhibitors. AstraZeneca in breast cancer Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death. AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in earlier lines of treatment and in new breast cancer settings. In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines fulvestrant and goserelin and aims to reshape the HR-positive space with first-in-class AKT inhibitor, capivasertib, the TROP-2-directed ADC, datopotamab deruxtecan-dlnk and next-generation oral SERD and potential new medicine camizestrant. PARP inhibitor olaparib is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with Merck & Co., Inc. (MSD outside the US and Canada) continue to research olaparib in these settings and to explore its potential in earlier disease. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with camizestrant in BRCA -mutated, HR-positive, HER2-negative advanced breast cancer. To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of datopotamab deruxtecan-dlnk alone and in combination with immunotherapy durvalumab. AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @ AstraZeneca . References SOURCE: AstraZeneca